A Phase 3 interventional study of Roflumilast Foam and Vehicle Foam in Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 53 sites in 2 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dermatitis, Seborrheic with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Dermatitis, Seborrheic · United States.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 3, and was the 15th registered.
58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.
Browse Dermatitis, Seborrheic studies →1 of the 19 studies in Dermatitis, Seborrheic with a site in United States is open now. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 457 is above the median of 77 across 47 interventional studies indexed under Dermatitis, Seborrheic.
Median enrollment 62 across the 18 interventional studies, 32 across the 1 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
Arcutis Biotherapeutics, Inc. has 3 studies filed under Dermatitis, Seborrheic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.
Drug: Roflumilast Foam
Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.
Drug: Vehicle Foam
Roflumilast 0.3% foam for topical application
Also known as: ARQ-154
Vehicle foam for topical application
Achievement of Success on the Investigator Global Assessment (IGA) at Week 8
The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].
Time frame: Week 8
Achievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 8
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 8.
Time frame: Week 8
Achievement of Success in the WI-NRS at Week 4
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 4.
Time frame: Week 4
Achievement of Success in the WI-NRS at Week 2
The percentage of participants achieving WI-NRS "success" is presented. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2. The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity).
Time frame: Week 2
Achievement of Success on the IGA at Week 2
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2.
Time frame: Week 2
Achievement of Success on the IGA at Week 4
The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].
Time frame: Week 4
Achievement of Overall Assessment of Scaling Score of 0 at Week 8
The percentage of participants achieving Overall Assessment of Scaling score of 0 at Week 8 is presented. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater symptom severity.
Time frame: Week 8
Achievement of Overall Assessment of Erythema Score of 0 at Week 8
The percentage of participants achieving Overall Assessment of Erythema score of 0 at Week 8 is presented. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
Time frame: Week 8
| Milestone | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Started | 304 | 153 |
| Completed | 276 | 138 |
| Not completed | 28 | 15 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Lost to follow-up | 12 | 4 |
| Withdrew: Withdrawal by subject | 11 | 4 |
| Withdrew: Did not tolerate application | 1 | 0 |
| Withdrew: Wanted to early terminate and use own product | 0 | 1 |
| Withdrew: Missed visits due to new work schedule | 1 | 0 |
The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 | 80 (74 to 84) | 58 (50 to 66) |
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 8.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 8 | 63 (56 to 70) | 41 (31 to 51) |
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 4.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success in the WI-NRS at Week 4 | 48 (41 to 54) | 29 (21 to 39) |
The percentage of participants achieving WI-NRS "success" is presented. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2. The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity).
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success in the WI-NRS at Week 2 | 33 (27 to 40) | 16 (10 to 24) |
The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success on the IGA at Week 2 | 43 (37 to 49) | 26 (19 to 33) |
The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Success on the IGA at Week 4 | 73.1 (67.67 to 77.83) | 47.1 (39.19 to 55.10) |
The percentage of participants achieving Overall Assessment of Scaling score of 0 at Week 8 is presented. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Overall Assessment of Scaling Score of 0 at Week 8 | 58 (52 to 63) | 37 (29 to 45) |
The percentage of participants achieving Overall Assessment of Erythema score of 0 at Week 8 is presented. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Overall Assessment of Erythema Score of 0 at Week 8 | 58 (52 to 63) | 32 (25 to 40) |
Collected over Up to ~8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Foam 0.3% | 0/304 (0%) | 1/304 (0.3%) | 0/304 (0%) |
| Vehicle Foam | 0/153 (0%) | 0/153 (0%) | 0/153 (0%) |
| Event | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/304 | 0/153 |
| Age, Continuous(years) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 43.2 ± 16.81 | 41.8 ± 17.47 | 42.7 ± 17.03 |
| Sex: Female, Male(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Female | 151 | 78 | 229 |
| Male | 153 | 75 | 228 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Hispanic or Latino | 69 | 28 | 97 |
| Not Hispanic or Latino | 235 | 125 | 360 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 0 | 4 |
| Asian | 18 | 10 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 36 | 15 | 51 |
| White | 234 | 122 | 356 |
| More than one race | 1 | 1 | 2 |
| Other | 11 | 4 | 15 |
| Investigator Global Assessment (IGA) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 2 - Mild | 0 | 0 | 0 |
| 3 - Moderate | 287 | 141 | 428 |
| 4 - Severe | 17 | 12 | 29 |
| Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 0 | 20 | 9 | 29 |
| 1 | 13 | 14 | 27 |
| 2 | 22 | 10 | 32 |
| 3 | 35 | 16 | 51 |
| 4 | 26 | 15 | 41 |
| 5 | 43 | 20 | 63 |
| 6 | 40 | 22 | 62 |
| 7 | 39 | 17 | 56 |
| 8 | 33 | 16 | 49 |
| 9 | 14 | 7 | 21 |
| 10 | 12 | 6 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Apr 2022, 8 months.
Results were first posted in Mar 2024, 1 year 11 months after primary completion. A results delay was requested in Mar 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARQ-154
Arcutis Biotherapeutics, Inc. →